The results highlight the underappreciated burden of diabetic foot hospitalizations not associated with amputation, the authors said.
Patients with type 1 diabetes and a mean three-year HbA1c level greater than 8.0% had a higher fracture risk than those with a mean three-year HbA1c level of 7.0% or less.
Patients with type 1 diabetes who were randomly assigned to insulin treatment with a closed-loop system spent more time in the target glycemic range than those assigned to a sensor-augmented pump.
Real-time continuous glucose monitoring (CGM), with either an insulin pump or multiple daily injections, was associated with sustained improvements in HbA1c levels compared to self-monitoring of blood glucose, according to a small randomized trial.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with fewer hospitalizations for heart failure and slower progression of kidney disease while glucagon-like peptide-1 (GLP-1) receptor agonists were associated with lower risk of stroke
In a longitudinal study of 21,531 patients, those in poor or intermediate health at age 75 years were more likely to use insulin than those in good health (29.4% and 27.5% versus 10.5%, respectively) and less likely to discontinue it during follow-up
In a survey of U.S. adults with diabetes, about 13% who were prescribed medication said they did not take it as prescribed, and about 24% said they asked their doctors for a lower-cost medication.
Patients' perceived helpfulness of certain actions by health care professionals was linked to earlier insulin initiation and greater insulin continuation over time, a survey found.
Patients with diabetes and obesity who had metabolic surgery were matched in a 1:5 ratio to those who received usual care, with incidence of a major cardiovascular event (MACE) as the primary outcome.
The comparison of dipeptidyl peptidase-4 inhibitors with other drug classes did find higher rates of major adverse cardiovascular events with basal insulin, sulfonylureas, and meglitinides than with the newer drugs.